Aimmune Therapeutics (NASDAQ: [[ticker:AIMT]]) has appointed Andrew Oxtoby to serve as its chief commercial officer. Oxtoby comes to Brisbane, CA-based Aimmune after 16 years at Eli Lilly (NYSE: [[ticker:LLY]]), most recently as vice president of U.S. diabetes connected care and insulins. Aimmune is awaiting an FDA decision on its experimental peanut-allergy treatment, AR101.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
